BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
BioAge Labs, Inc.NASDAQ: BIOA
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 21.1% from a year ago
Total equity stood at $379.12M at the end of Q1 FY2026, up 21.1% from a year earlier and up 39.4% from the prior quarter.
Context
- Total equity amounted to 95.3% of total assets at the end of Q1 FY2026, up 4.3 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +21.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 272.05M USD
- Year-over-year change
- -15.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 272.05M | -15.8% |
| FY2024 | 2024-12-31 | 323.13M | +286.4% |
| FY2023 | 2023-12-31 | (173.4M) | -54.0% |
| FY2022 | 2022-12-31 | (112.56M) | — |
Total Equity vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +21.1% is the 2nd highest of 9, against a peer median of -22.5%.
- Total equity amounts to 95.3% of total assets for BIOA, versus a peer median of 65.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$697.59M CAD | +43.2% | +8.6% | 62.4% | |
| Mar 2026 | CA$513.15M CAD | -15.2% | -0.6% | 85.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $379.12M USD | +21.1% | — | 95.3% |
| Mar 2026 | $278.88M USD | -27.6% | -24.0% | 70.4% | |
| Mar 2026 | $233.71M USD | -43.1% | -24.5% | 87.5% | |
| Mar 2026 | $103.31M USD | -15.0% | +2.3% | 69.7% | |
| Mar 2026 | $64.92M USD | -17.4% | -11.7% | 65.8% | |
| Mar 2026 | $11.62M USD | -67.7% | -70.2% | 10.5% | |
| Mar 2026 | $4.41M USD | -92.9% | -57.7% | 3.0% | |
| Dec 2025 | -$14.2M USD | — | — | 6.1% | |
| Peer median (excluding BIOA) | — | -22.5% | -17.9% | 65.8% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.